Overview

Use of 852A in Metastatic Cutaneous Melanoma.

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer